Duff & de la Cruz: Pfizer’s $650 Million Groton Investment Is a Bet on Connecticut
News originally published by
Connecticut Senate Democrats
“Pfizer could have built this anywhere in the world, and it chose Groton. This $650 million investment is a bet on Connecticut: on our workforce, our research base, and the decades of work that made southeastern Connecticut a home for science. This is a long-term commitment to the people already working on that campus and to the whole region around it.
–Senate Majority Leader Bob Duff (D-Norwalk) on Pfizer’s announcement of a new Manufacturing Technology Center in Groton.
“Pfizer has been part of Groton for as long as I can remember. My neighbors work there, and this investment keeps that work here for the long haul. I spent my career in the trades, and I know what a project this size means: years of work for the carpenters, electricians, sheet metal workers, and laborers who will build it. And when the construction crews leave, the jobs stay. This puts the scientists and technicians on that campus in a modern facility built for the next generation of medicines, and that keeps good-paying jobs anchored in the region for decades to come.
–Senator-elect Joe de la Cruz (D-Groton) on the same announcement.
Pfizer plans to build an approximately 220,000-square-foot Manufacturing Technology Center at its Groton research and development campus, a $650 million capital investment over the next five years. The facility will produce clinical drug ingredients and drug products for Pfizer clinical trials worldwide. Construction is planned to begin in the second quarter of 2027, with operations targeted for mid-2031.
FOR IMMEDIATE RELEASE
Contact: Kevin Coughlin | 203-710-0193 | kevin.coughlin@cga.ct.gov
Share this page:
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
